Floatz Rating
B60/100
Confidence
Indicative
Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00119119CT.gov Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fibrotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tocopherol (this asset) | French National Agency for Research on AIDS and Viral Hepatitis | P3 | B · 60 |
| Entecavir | Tanta University | P4 | BB |
| Peg-Intron | Beth Israel Deaconess Medical Center | P4 | BB |
| Colchicinum | Zagazig University | P4 | BB |
| Peg-Ifn | Beijing Friendship Hospital | P4 | BB |
| Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | P3 | BB |
| A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness | Bristol-Myers Squibb | P2 | BB |
| Ribavirin | ANRS, Emerging Infectious Diseases | P3 | BB |
| Losartan | Hospital Clinic of Barcelona | P4 | BB |
+42 more in the Fibrotic Liver Disease cohort
Other indications for Tocopherol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | B · 62 |
| Breast Cancer | — | P3 | B · 60 |
| Chronic Hepatitis C Virus Infection | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tocopherol in Fibrotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tocopherol-fibrotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →